Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 61.72 Billion KRW | 0.58% |
| 2022 | 61.37 Billion KRW | 48.99% |
| 2021 | 41.19 Billion KRW | -15.23% |
| 2020 | 48.58 Billion KRW | -9.09% |
| 2019 | 53.45 Billion KRW | 7.89% |
| 2018 | 49.54 Billion KRW | -4.39% |
| 2017 | 51.81 Billion KRW | 7.04% |
| 2016 | 48.4 Billion KRW | -1.91% |
| 2015 | 49.34 Billion KRW | 4.5% |
| 2014 | 47.22 Billion KRW | 58.66% |
| 2013 | 29.76 Billion KRW | 8.98% |
| 2012 | 27.31 Billion KRW | -2.22% |
| 2011 | 27.93 Billion KRW | 18.4% |
| 2010 | 23.59 Billion KRW | -0.47% |
| 2009 | 23.7 Billion KRW | 24.16% |
| 2008 | 19.08 Billion KRW | -12.32% |
| 2007 | 21.77 Billion KRW | 23.33% |
| 2006 | 17.65 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 76.55 Billion KRW | 11.42% |
| 2024 Q1 | 68.7 Billion KRW | 11.31% |
| 2023 FY | 61.72 Billion KRW | 0.58% |
| 2023 Q4 | 61.72 Billion KRW | -15.42% |
| 2023 Q3 | 72.97 Billion KRW | 3.07% |
| 2023 Q2 | 70.8 Billion KRW | 11.32% |
| 2023 Q1 | 63.6 Billion KRW | 3.65% |
| 2022 Q4 | 61.37 Billion KRW | 5.25% |
| 2022 Q3 | 58.31 Billion KRW | -3.74% |
| 2022 FY | 61.37 Billion KRW | 48.99% |
| 2022 Q1 | 47.71 Billion KRW | 15.83% |
| 2022 Q2 | 60.57 Billion KRW | 26.96% |
| 2021 Q4 | 41.19 Billion KRW | -16.8% |
| 2021 Q1 | 48.95 Billion KRW | 0.76% |
| 2021 Q2 | 56.23 Billion KRW | 14.86% |
| 2021 Q3 | 49.5 Billion KRW | -11.96% |
| 2021 FY | 41.19 Billion KRW | -15.23% |
| 2020 Q4 | 48.58 Billion KRW | -3.4% |
| 2020 Q1 | 57.9 Billion KRW | 8.34% |
| 2020 Q3 | 50.3 Billion KRW | -21.23% |
| 2020 FY | 48.58 Billion KRW | -9.09% |
| 2020 Q2 | 63.86 Billion KRW | 10.28% |
| 2019 Q2 | 60.14 Billion KRW | 19.12% |
| 2019 FY | 53.45 Billion KRW | 7.89% |
| 2019 Q4 | 53.45 Billion KRW | -2.69% |
| 2019 Q3 | 54.92 Billion KRW | -8.68% |
| 2019 Q1 | 50.49 Billion KRW | 1.92% |
| 2018 Q3 | 58.34 Billion KRW | -6.44% |
| 2018 Q4 | 49.54 Billion KRW | -15.09% |
| 2018 FY | 49.54 Billion KRW | -4.39% |
| 2018 Q1 | 54.99 Billion KRW | 6.12% |
| 2018 Q2 | 62.36 Billion KRW | 13.41% |
| 2017 FY | 51.81 Billion KRW | 7.04% |
| 2017 Q3 | 53.47 Billion KRW | -12.83% |
| 2017 Q2 | 61.34 Billion KRW | 12.86% |
| 2017 Q1 | 54.35 Billion KRW | 12.29% |
| 2017 Q4 | 51.81 Billion KRW | -3.1% |
| 2016 Q1 | 50.19 Billion KRW | 0.0% |
| 2016 Q3 | 43.94 Billion KRW | -20.39% |
| 2016 Q2 | 55.2 Billion KRW | 10.0% |
| 2016 FY | 48.4 Billion KRW | -1.91% |
| 2016 Q4 | 48.4 Billion KRW | 10.15% |
| 2015 FY | 49.34 Billion KRW | 4.5% |
| 2015 Q3 | 45.77 Billion KRW | -11.75% |
| 2015 Q2 | 51.86 Billion KRW | 9.83% |
| 2015 Q1 | 47.22 Billion KRW | 8.32% |
| 2014 FY | 47.22 Billion KRW | 58.66% |
| 2014 Q2 | 43.48 Billion KRW | 46.11% |
| 2014 Q4 | 43.59 Billion KRW | -9.65% |
| 2014 Q3 | 48.25 Billion KRW | 10.96% |
| 2014 Q1 | 29.76 Billion KRW | 0.0% |
| 2013 FY | 29.76 Billion KRW | 8.98% |
| 2013 Q1 | 27.31 Billion KRW | -4.91% |
| 2012 Q4 | 28.72 Billion KRW | 5.89% |
| 2012 Q3 | 27.12 Billion KRW | 5.61% |
| 2012 Q1 | 27.93 Billion KRW | -8.76% |
| 2012 FY | 27.31 Billion KRW | -2.22% |
| 2012 Q2 | 25.68 Billion KRW | -8.05% |
| 2011 Q2 | 25.6 Billion KRW | 8.53% |
| 2011 FY | 27.93 Billion KRW | 18.4% |
| 2011 Q1 | 23.59 Billion KRW | -10.0% |
| 2011 Q3 | 29.41 Billion KRW | 14.88% |
| 2011 Q4 | 30.61 Billion KRW | 4.08% |
| 2010 Q3 | 23.16 Billion KRW | -2.31% |
| 2010 Q4 | 26.21 Billion KRW | 13.16% |
| 2010 Q2 | 23.71 Billion KRW | 0.0% |
| 2010 FY | 23.59 Billion KRW | -0.47% |
| 2009 Q1 | 19.08 Billion KRW | -12.14% |
| 2009 FY | 23.7 Billion KRW | 24.16% |
| 2009 Q4 | 22.69 Billion KRW | 2.02% |
| 2009 Q3 | 22.25 Billion KRW | -15.94% |
| 2009 Q2 | 26.46 Billion KRW | 38.66% |
| 2008 Q2 | 22.73 Billion KRW | 4.43% |
| 2008 Q1 | 21.77 Billion KRW | 14.09% |
| 2008 Q4 | 21.72 Billion KRW | 3.38% |
| 2008 Q3 | 21.01 Billion KRW | -7.57% |
| 2008 FY | 19.08 Billion KRW | -12.32% |
| 2007 Q3 | 17.93 Billion KRW | 4.73% |
| 2007 FY | 21.77 Billion KRW | 23.33% |
| 2007 Q4 | 19.08 Billion KRW | 6.4% |
| 2007 Q2 | 17.12 Billion KRW | 0.0% |
| 2006 FY | 17.65 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -39.8% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 47.625% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 32.294% |
| HANDOK Inc. | 94.46 Billion KRW | 34.658% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -190.563% |
| Yuhan Corporation | 284.75 Billion KRW | 78.324% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 46.933% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -279.641% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 78.628% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -90.601% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -216.91% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -103.845% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -27.669% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -39.8% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -97.577% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -75.472% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -28.251% |
| JW Holdings Corporation | 147.58 Billion KRW | 58.178% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 27.06% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 76.39% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.819% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -14.468% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -128.627% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -89.855% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 43.768% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -39.8% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 67.28% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 74.446% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.819% |
| Yuhan Corporation | 284.75 Billion KRW | 78.324% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 50.731% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 0.423% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 76.245% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.819% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 22.459% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -25.605% |
| CKD Bio Corp. | 69.08 Billion KRW | 10.65% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 41.258% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 12.691% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -14.182% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -14.468% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 68.308% |
| Boryung Corporation | 189.8 Billion KRW | 67.48% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -8.609% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 0.0% |
| JW Lifescience Corporation | 23.39 Billion KRW | -163.796% |